Alvotech Swiss Ag
Clinical trials sponsored by Alvotech Swiss Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug AVT29 takes on eylea HD in DME trial Results expected Jul 2027 (estimated)
-
New keytruda copycat tested for melanoma prevention
Disease control Recruiting nowThis trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…
Phase 1 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New eye drug AVT29 takes on eylea HD in DME trial
Disease control Recruiting nowThis study tests a new medicine called AVT29 against an approved drug, Eylea HD, for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 256 adults with DME will receive either AVT29 or Eylea HD to see if AVT29 works just as well at improvi…
Phase 3 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC